AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33294862 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline immune features analysis
Number of subjects: 21
Study 33294860 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade
Number of subjects: 0
Study 33294861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (monoclonal anti-IL-6 receptor) treatment
Number of subjects: 0
Study 33294918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0
Study 33294918 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study 33295204 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Management Program
Number of subjects: 20
Study 33295204 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 20
Study 33295277 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS) therapy
Number of subjects: 126
Study 33295643 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 12127
Study 33295823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy (NHFT) with heated humidified air (flow: 40 L/min with 80% oxygen) during breath-hold (BH) training and treatment.
Number of subjects: 10
Study 33295823 — intervention group
Group type: COMPARATOR
Intervention: Nasal high-flow therapy (NHFT) during breath-hold (BH) training and treatment.
Number of subjects: 10
Study 33296036 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW group (0.63 gI/kg of LBW)
Number of subjects: 274
Study 33296036 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW group
Number of subjects: 274
Study 33296036 — intervention group
Group type: COMPARATOR
Intervention: TBW group
Number of subjects: 274
Study 33296042 — intervention group
Group type: EXPERIMENTAL
Intervention: ORM-12741
Number of subjects: 0
Study 33296127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 kHz spinal cord stimulation
Number of subjects: 0
Study 33296242 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years)
Number of subjects: 157
Study 33296242 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 157
Study 33296533 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation Testing (DT) performed in 254 patients (DT+ group)
Number of subjects: 420
Study 33296533 — intervention group
Group type: COMPARATOR
Intervention: No Defibrillation Testing (DT) in 166 patients (DT- group)
Number of subjects: 420
Study 33296696 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anterior insula
Number of subjects: 157
Study 33296696 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventral-posterior insula
Number of subjects: 157
Study 33296696 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventral-posterior insular structural covariance
Number of subjects: 157
Study 33296696 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain SBNs (salience network, default mode network, central executive network)
Number of subjects: 157
Study 33296830 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P/G)
Number of subjects: 299
Study 33296868 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based survey during COVID-19 confinement
Number of subjects: 0
Study 33296868 — intervention group
Group type: EXPERIMENTAL
Intervention: Second web-based survey 1 year after lockdown
Number of subjects: 0
Study 33297779 — intervention group
Group type: EXPERIMENTAL
Intervention: Various biomarkers (genetic, plasmatic, cellular, microbiome-related) studied for GVHD diagnosis and prognosis.
Number of subjects: 0
Study 33297779 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment tailored to patients' needs based on biomarker identification.
Number of subjects: 0
Study 33297794 — intervention group
Group type: EXPERIMENTAL
Intervention: idelalisib
Number of subjects: 0
Study 33297800 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular neck stems
Number of subjects: 75
Study 33297800 — intervention group
Group type: COMPARATOR
Intervention: Standard neck stems
Number of subjects: 75
Study 33297819 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33297992 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF; healthy school lunch and structured physical activity)
Number of subjects: 1676
Study 33297992 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary School of the Future (HPSF)
Number of subjects: 1676
Study 33297992 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity School (PAS; structured physical activity)
Number of subjects: 1676
Study 33297992 — intervention group
Group type: COMPARATOR
Intervention: Control schools (regular Dutch curriculum)
Number of subjects: 1676
Study 33298010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 245
Study 33298010 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 245
Study 33298159 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET), up to six sessions with partial telehealth delivery
Number of subjects: 8
Study 33298159 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 8
Study 33298471 — intervention group
Group type: EXPERIMENTAL
Intervention: Precarious circumstances with situational facilitators
Number of subjects: 2066
Study 33298471 — intervention group
Group type: COMPARATOR
Intervention: Precarious circumstances without situational facilitators
Number of subjects: 2066
Study 33298471 — intervention group
Group type: COMPARATOR
Intervention: Marginalisation
Number of subjects: 2066
Study 33298471 — intervention group
Group type: COMPARATOR
Intervention: Clinical presentation
Number of subjects: 2066
Study 33298619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab combined with bempegaldesleukin (BEMPEG, NKTR-214)
Number of subjects: 1
Study 33298619 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 1
Study 33298619 — intervention group
Group type: COMPARATOR
Intervention: bempegaldesleukin (BEMPEG, NKTR-214)
Number of subjects: 1
Study 33299539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) measuring mean flow velocities (MFVs) of cerebral arteries
Number of subjects: 40
Study 33299539 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hydrocephalus and delayed cerebral ischemia (DCI)
Number of subjects: 40
Study 33299539 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased mean flow velocities (MFV)
Number of subjects: 40
Study 33300144 — intervention group
Group type: EXPERIMENTAL
Intervention: African-ancestry weighted genetic risk score (AFR wGRS)
Number of subjects: 0
Study 33300144 — intervention group
Group type: EXPERIMENTAL
Intervention: European-ancestry weighted genetic risk score (EUR wGRS)
Number of subjects: 0
Study 33300144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-ancestry weighted genetic risk score
Number of subjects: 0
Study 33300144 — intervention group
Group type: COMPARATOR
Intervention: AFR wGRS
Number of subjects: 0
Study 33300151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMB) in DLB patients
Number of subjects: 158
Study 33300151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMB) in AD patients
Number of subjects: 158
Study 33300151 — intervention group
Group type: COMPARATOR
Intervention: Cerebral microbleeds (CMB) in DLB patients with and without CMB
Number of subjects: 158
Study 33300372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 0
Study 33300403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-sensitive prostate cancer (HSPC)
Number of subjects: 1869
Study 33300403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic hormone-sensitive prostate cancer (mHSPC)
Number of subjects: 1869
Study 33300403 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-metastatic castration-resistant prostate cancer (nmCRPC)
Number of subjects: 1869
Study 33300403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic castration-resistant prostate cancer (mCRPC)
Number of subjects: 1869
Study 33300403 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (HRU) costs
Number of subjects: 1869
Study 33300564 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site anorectal and pharyngeal testing
Number of subjects: 0
Study 33300564 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site (anorectum and urethra/cervix) testing
Number of subjects: 0
Study 33300564 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-site testing
Number of subjects: 0
Study 33301080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model for sudden death (SD)
Number of subjects: 4116
Study 33301080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model for pump failure death (PFD)
Number of subjects: 4116
Study 33301080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of NT-proBNP in the SD model
Number of subjects: 4116
Study 33301080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of ECG and biochemical parameters
Number of subjects: 4116
Study 33301227 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib 300 mg once daily
Number of subjects: 250
Study 33301227 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib with dose modification
Number of subjects: 250
Study 33301227 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib without dose modification
Number of subjects: 250
Study 33301375 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0250 (8 mg/kg, once every 2 weeks)
Number of subjects: 45
Study 33301375 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0250 (12 mg/kg, once every 2 weeks)
Number of subjects: 45
Study 33301375 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0250 (various doses)
Number of subjects: 45
Study 33301375 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0250
Number of subjects: 45
Study 33301630 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (initiated within the first seven days after birth)
Number of subjects: 910
Study 33301630 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early treatment (initiated within the first 72 hours after birth)
Number of subjects: 910
Study 33301930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 20
Study 33301930 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 33302031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin monotherapy
Number of subjects: 122
Study 33302031 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin in combination with cytarabine
Number of subjects: 122
Study 33302031 — intervention group
Group type: COMPARATOR
Intervention: Idasanutlin (MBP formulation)
Number of subjects: 122
Study 33302031 — intervention group
Group type: COMPARATOR
Intervention: Idasanutlin (SDP formulation)
Number of subjects: 122
Study 33302031 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 122
Study 33302031 — intervention group
Group type: COMPARATOR
Intervention: Early death rate
Number of subjects: 122
Study 33302114 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors
Number of subjects: 94
Study 33302225 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD with EEG changes
Number of subjects: 100
Study 33302225 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD with epilepsy
Number of subjects: 100
Study 33302225 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD without EEG changes
Number of subjects: 100
Study 33302225 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 100
Study 33302225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy
Number of subjects: 100
Study 33302264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-18 and carbon-13 isotopes in eCO
Number of subjects: 0
Study 33302891 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside >1000 mg
Number of subjects: 256
Study 33302891 — intervention group
Group type: COMPARATOR
Intervention: Iron isomaltoside ≤1000 mg
Number of subjects: 256
Study 33303023 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS; MSPrebiotic®, N = 38)
Number of subjects: 75
Study 33303023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 37)
Number of subjects: 75
Study 33303023 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant potato starch (RPS; MSPrebiotic®)
Number of subjects: 75
Study 33303117 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous edge-to-edge mitral valve repair (PMVR)
Number of subjects: 106
Study 33303117 — intervention group
Group type: COMPARATOR
Intervention: Staged PMVR
Number of subjects: 106
Study 33303117 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter interventions
Number of subjects: 106
Study 33303117 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 106
Study 33303435 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA and FFR based surgical revascularisation
Number of subjects: 0
Study 33303463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Chinese version of UCLA 3-item Loneliness Scale
Number of subjects: 1653
Study 33303463 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness score of 3
Number of subjects: 1653
Study 33303471 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship programme (ASP)
Number of subjects: 0
Study 33303471 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on antimicrobial use and susceptibility of organisms
Number of subjects: 0
Study 33303470 — intervention group
Group type: EXPERIMENTAL
Intervention: Confinement group
Number of subjects: 927
Study 33303470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemic group
Number of subjects: 927
Study 33303470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 927
Study 33303470 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Confinement, Epidemic, Control)
Number of subjects: 927
Study 33303537 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing MRI
Number of subjects: 0
Study 33303539 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 recovery evaluation at 100 days
Number of subjects: 145
Study 33303539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function analysis
Number of subjects: 145
Study 33303539 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 145
Study 33303539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential follow-up evaluations at 60 and 100 days
Number of subjects: 145
Study 33303555 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood eosinophil count of ≥300 cells·µL
Number of subjects: 1120
Study 33303555 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1120
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisation for COPD after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation frequency after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of body mass index after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow obstruction after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnoea and exercise (BODE index) after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status (St George's Respiratory Questionnaire (SGRQ)) after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of systemic inflammation after 1 year
Number of subjects: 0
Study 33303557 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 1 s (FEV1) at 3 years
Number of subjects: 0
Study 33303567 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site treatment with sofosbuvir/velpatasvir
Number of subjects: 2323
Study 33303567 — intervention group
Group type: EXPERIMENTAL
Intervention: Link-to-care treatment
Number of subjects: 2323
Study 33303567 — intervention group
Group type: COMPARATOR
Intervention: Overall HCV-viremic rate
Number of subjects: 2323
Study 33303567 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV microelimination
Number of subjects: 2323
Study 33303567 — intervention group
Group type: EXPERIMENTAL
Intervention: 'No-C HD' (no HCV-viremic subjects)
Number of subjects: 2323
Study 33303707 — intervention group
Group type: EXPERIMENTAL
Intervention: Rixubis (recombinant factor IX, nonacog gamma)
Number of subjects: 58
Study 33303745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of RANK signaling in mouse tumor cells
Number of subjects: 0
Study 33303900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) DM (+)
Number of subjects: 1007
Study 33303900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) DM (-)
Number of subjects: 1007
Study 33303900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (-) DM (+)
Number of subjects: 1007
Study 33303900 — intervention group
Group type: COMPARATOR
Intervention: Sleep apnea (-) DM (-)
Number of subjects: 1007
Study 33303900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep apnea (+) and DM (+)
Number of subjects: 1007
Study 33304267 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive VRRS followed by telerehabilitation (36 sessions of home-based cognitive VRRS training, three sessions per week)
Number of subjects: 49
Study 33304267 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive VRRS followed by at-home unstructured cognitive stimulation (36 sessions, three sessions per week)
Number of subjects: 49
Study 33304267 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive treatment as usual (12 sessions)
Number of subjects: 49
Study 33304282 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg CBD
Number of subjects: 60
Study 33304282 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg THC
Number of subjects: 60
Study 33304282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cannabinoids (800 mg CBD and 20 mg THC)
Number of subjects: 60
Study 33304282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33304914 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO2R)
Number of subjects: 0
Study 33304914 — intervention group
Group type: COMPARATOR
Intervention: Lung-protective ventilation
Number of subjects: 0
Study 33304950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 581
Study 33305066 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter prescription (Laughie recording three times daily for 14 days)
Number of subjects: 40
Study 33305066 — intervention group
Group type: COMPARATOR
Intervention: Control group (only tracking sleep)
Number of subjects: 40
Study 33305350 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions (dietary changes, diet and exercise, diet and psychosocial support, diet, exercise and psychosocial support)
Number of subjects: 2028
Study 33305350 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions
Number of subjects: 2028
Study 33305350 — intervention group
Group type: COMPARATOR
Intervention: Usual care, written materials, placebo, or wait-list controls
Number of subjects: 2028
Study 33305440 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 89
Study 33305842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 to 2000 IU daily; or up to 300,000 IU bolus at enrolment)
Number of subjects: 12122
Study 33305842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 to 6000 IU daily; or up to 600,000 IU bolus at enrolment)
Number of subjects: 12122
Study 33305842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose vitamin D supplementation with micronutrients (400 to 2000 IU daily, or up to 300,000 IU bolus at enrolment)
Number of subjects: 12122
Study 33305842 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose vitamin D supplementation
Number of subjects: 12122
Study 33306031 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOSTH exergame
Number of subjects: 16
Study 33306036 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH2CHECK intervention (community health nursing visits and SMS messaging)
Number of subjects: 120
Study 33306036 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) control group
Number of subjects: 120
Study 33306161 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 20
Study 33306161 — intervention group
Group type: COMPARATOR
Intervention: Without empagliflozin (Control)
Number of subjects: 20
Study 33306187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (mean daily dose 12.7 mg, mean treatment duration 28.0 days)
Number of subjects: 100
Study 33306563 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mentor mother visits alone
Number of subjects: 1275
Study 33306563 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages alone
Number of subjects: 1275
Study 33306563 — intervention group
Group type: COMPARATOR
Intervention: Preconception ART initiation
Number of subjects: 1275
Study 33306563 — intervention group
Group type: COMPARATOR
Intervention: Postconception ART initiation
Number of subjects: 1275
Study 33306598 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2RA immunohistochemistry (IHC)
Number of subjects: 123
Study 33306598 — intervention group
Group type: EXPERIMENTAL
Intervention: alanine aminotransferase (ALT)
Number of subjects: 123
Study 33306598 — intervention group
Group type: EXPERIMENTAL
Intervention: IL2RA IHC
Number of subjects: 123
Study 33306625 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-anti-TNF-α scintigraphy
Number of subjects: 20
Study 33307033 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive tests (NITs) for fibrosis
Number of subjects: 2154
Study 33307033 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in NIT scores during treatment
Number of subjects: 2154